|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.38 | 89.41 | 104.18 | 0.54 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
364.00
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
|
(Rs. in Million) | Particulars | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Audited / UnAudited | UnAudited | UnAudited | UnAudited | Audited | Net Sales | 2,017.78 | 2,148.74 | 1,950.20 | 1,730.36 | Total Expenditure | 1,653.23 | 1,755.04 | 1,595.42 | 1,408.87 | PBIDT (Excl OI) | 364.55 | 393.70 | 354.78 | 321.49 | Other Income | 4.24 | 3.34 | 8.81 | 6.23 | Operating Profit | 368.79 | 397.04 | 363.59 | 327.72 | Interest | 31.79 | 44.61 | 40.73 | 29.22 | Exceptional Items | 0 | 0 | 0 | 0 | PBDT | 337.00 | 352.43 | 322.86 | 298.50 | Depreciation | 41.42 | 42.97 | 42.36 | 59.18 | Profit Before Tax | 295.58 | 309.46 | 280.50 | 239.32 | Tax | 73.01 | 77.36 | 74.26 | 58.27 | Provisions and contingencies | 0 | 0 | 0 | 0 | Profit After Tax | 222.57 | 232.10 | 206.24 | 181.05 | Extraordinary Items | 0 | 0 | 0 | 0 | Prior Period Expenses | 0 | 0 | 0 | 0 | Other Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | Net Profit | 222.57 | 232.10 | 206.24 | 181.05 | Equity Capital | 100.28 | 96.94 | 96.94 | 96.94 | Face Value (IN RS) | 1 | 1 | 1 | 1 | Reserves | | | | | Calculated EPS | 2.22 | 2.39 | 2.13 | 1.87 | Calculated EPS (Annualised) | 8.88 | 9.58 | 8.51 | 7.47 | No of Public Share Holdings | 27,569,355.00 | 24,236,355.00 | 24,236,355.00 | 24,236,355.00 | % of Public Share Holdings | 27.49 | 25.00 | 25.00 | 25.00 | | | | | | PBIDTM% (Excl OI) | 18.07 | 18.32 | 18.19 | 18.58 | PBIDTM% | 18.28 | 18.48 | 18.64 | 18.94 | PBDTM% | 16.70 | 16.40 | 16.56 | 17.25 | PBTM% | 14.65 | 14.40 | 14.38 | 13.83 | PATM% | 11.03 | 10.80 | 10.58 | 10.46 | | Notes | Notes | Notes | Notes |
|
|
|
|
|
|